Asciminib
Overview
Asciminib is a small molecule ABL kinase inhibitor developed for the treatment of chronic myeloid leukemia (CML). It represents a novel therapeutic approach by specifically targeting the ABL myristoyl pocket.
API suppliers (2)
Suppliers of Asciminib evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.
Country recorded for 1 of 2 suppliers.
1 of 2 holds a GMP certificate on record in the EU or UK registers
- BIOPHORE INDIA PHARMACEUTICALS PVT LTD2 active DMF
- Hetero Labs LimitedIndia1 active DMF GMP on record
Patent & exclusivity (US)
Per the FDA Orange Book (3 approved US products), the latest listed US patent on Asciminib expires 17 May 2040 and exclusivity 29 Oct 2031. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
Do you supply Asciminib? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.